戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ertrophy (e.g., hypertrophic cardiomyopathy, hypertensive heart disease).
2 tion, and eventually clinical heart failure (hypertensive heart disease).
3 sure overload are valuable for understanding hypertensive heart disease.
4 ifferentiate between cardiac amyloidosis and hypertensive heart disease.
5 ommunicable disease such as hypertension and hypertensive heart disease.
6  5 amyloid transthyretin, and 4 control with hypertensive heart disease.
7 d the impact of microRNA-155 manipulation in hypertensive heart disease.
8 likely contributes to the modern epidemic of hypertensive heart disease.
9 ischemia/reperfusion, diabetes mellitus, and hypertensive heart disease.
10 of these antibodies was 17% in patients with hypertensive heart disease.
11 P overexpression and improves LV function in hypertensive heart disease.
12 ncluding ischemia/reperfusion, diabetes, and hypertensive heart disease.
13 dered metabolism that form the substrate for hypertensive heart disease.
14 tion, distinguishing HFpEF from pre-clinical hypertensive heart disease.
15 nt of heart failure symptoms in persons with hypertensive heart disease.
16 , functional, and clinical manifestations of hypertensive heart disease.
17 ntihypertensive classes and their effects on hypertensive heart disease.
18 cate that corin deficiency may contribute to hypertensive heart disease.
19 vention confers improved clinical outcome in hypertensive heart disease.
20 diastolic dysfunction very often accompanies hypertensive heart disease.
21 and functional changes associated with early hypertensive heart disease.
22 itial fibrosis resembling that seen in human hypertensive heart disease.
23 oups of participants across the continuum of hypertensive heart diseases.
24 .5 vs 5.1 deaths per 100000 persons) to 4.2 (hypertensive heart disease: 4.3 vs 17.9 deaths per 10000
25               These effects surpass those of hypertensive heart disease alone, supporting a direct ro
26        The proportionate mortality burden of hypertensive heart disease and cerebrovascular disease,
27  arrest, one gastric adenocarcinoma, and one hypertensive heart disease and congestive cardiac failur
28 erence was related to a greater frequency of hypertensive heart disease and congestive heart failure
29 y be applied to discriminate between HCM and hypertensive heart disease and detect early changes in G
30 obal metabolic demand identifies subclinical hypertensive heart disease and elevated risk of HF and d
31 pontaneously hypertensive rat (SHR) model of hypertensive heart disease and failure.
32 ased, whereas the proportion associated with hypertensive heart disease and idiopathic fibrosis has i
33 rosis is associated with adverse outcomes in hypertensive heart disease and may be reversible.
34                            Manifestations of hypertensive heart disease and of the aging heart appear
35 ution in rat models of pressure overload and hypertensive heart disease and significantly attenuated
36 lin D Roosevelt and his premature death from hypertensive heart disease and stroke in 1945.
37  and discuss the clinical characteristics of hypertensive heart disease and the genetic predispositio
38 isease (371266 coronary heart disease, 35019 hypertensive heart disease, and 99815 other cardiovascul
39 he human heart and mouse models of ischemia, hypertensive heart disease, and aortic stenosis.
40  mapping can discriminate between HCM versus hypertensive heart disease as well as to detect genetica
41 tensive patients with diastolic dysfunction (hypertensive heart disease) but no HF.
42 isease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomyopathy, atrial fibri
43 nced higher mortality rates for ischemic and hypertensive heart disease compared with other subgroups
44 ase, stroke, cardiomyopathy and myocarditis, hypertensive heart disease, diabetes, chronic kidney dis
45 ed in isolated myocardium from patients with hypertensive heart disease (HHD) and heart failure with
46                                              Hypertensive heart disease (HHD) occurs in patients that
47 arge diagnoses of systolic HF, diastolic HF, hypertensive heart disease (HHD) with HF, and HHD with H
48 bolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and,
49 cognition and interoception in patients with hypertensive heart disease (HHD).
50                     Hypertension can lead to hypertensive heart disease (HHD).
51                                              Hypertensive heart disease (HTN-HD) meaningfully contrib
52                                              Hypertensive heart disease involves a structural remodel
53 nduced cardiac effects, we hypothesized that hypertensive heart disease is associated with oxidative
54 and endothelin-1 (ET) in the pathogenesis of hypertensive heart disease is controversial.
55                             The incidence of hypertensive heart disease is increasing.
56       The clinical importance of fibrosis in hypertensive heart disease is now well recognized.
57 r tissue inhibitors [TIMPs]), are altered in hypertensive heart disease is unknown.
58 itions, such as hypertrophic cardiomyopathy, hypertensive heart disease, ischemic or other forms of n
59 a predominance of nonatherosclerotic stroke, hypertensive heart disease, nonischemic and Chagas cardi
60 e with an ejection fraction <50%, those with hypertensive heart disease of the elderly, and those wit
61         Compared to both normal controls and hypertensive heart disease patients, the HFpEF patients
62 ia (relative risk, 6.0; 95% CI, 4.5 to 8.1), hypertensive heart disease (relative risk, 2.4; 95% CI,
63                       Myocardial fibrosis in hypertensive heart disease remains an area of intensive
64  rural South Africa, with a larger burden of hypertensive heart disease than previously appreciated,
65 ath, including prostate cancer, myeloma, and hypertensive heart disease, the higher death rates among
66     Mechanisms promoting the transition from hypertensive heart disease to heart failure with preserv
67 ortant for clinicians to identify and manage hypertensive heart disease to prevent increased morbidit
68 nfarction and trauma but not cardiomyopathy, hypertensive heart disease, valvular heart disease, cere
69  tissue volume fraction in a rodent model of hypertensive heart disease, whereas the widely used anal
70 rtic constriction mice displayed compensated hypertensive heart disease with hypertrophy, increased o
71           Proportion of SCDs associated with hypertensive heart disease with left ventricular hypertr
72               Additionally, 35 patients with hypertensive heart disease with preserved ejection fract